ArticlePloS one2015
MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.The American journal of tropical medicine and hygiene · 2018Pooled it
- Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis.Medicine · 2016Pooled it
- Circulating multi-omic signature of disease severity and cholangiocarcinoma in primary sclerosing cholangitis.Hepatology communications · 2026Article
- Advancing Cholangiocarcinoma Diagnosis: The Role of Liquid Biopsy and CRISPR/Cas Systems in Biomarker Detection.Cancers · 2025Review
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications.Cancers · 2024Review
- RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.Frontiers in molecular biosciences · 2024Review
- Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.Cancers · 2023Review
- Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.JHEP reports : innovation in hepatology · 2023Article
- Targeted therapies in advanced biliary tract cancers-a narrative review.Chinese clinical oncology · 2023Review
- Article
- Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma.Genes · 2022Review
- Review
- The current state of molecular profiling in gastrointestinal malignancies.Biology direct · 2022Review
- Comprehensive Evaluation and Application of a Novel Method to Isolate Cell-Free DNA Derived From Bile of Biliary Tract Cancer Patients.Frontiers in oncology · 2022Article
- Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.Frontiers in immunology · 2022Review
- Prioritizing key synergistic circulating microRNAs for the early diagnosis of biliary tract cancer.Frontiers in oncology · 2022Article
- Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives.Exploration of targeted anti-tumor therapy · 2022Review
- Potential utility of miRNAs for liquid biopsy in breast cancer.Frontiers in oncology · 2022Review
- Meta-analysis and systematic review of liver transplantation as an ultimate treatment option for secondary sclerosing cholangitis.Przeglad gastroenterologiczny · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPatients with primary sclerosing cholangitis (PSC) are at high risk for the development of cholangiocarcinoma (CC). Analysis of micro ribonucleic acid (MiRNA) patterns is an evolving research field in biliary pathophysiology with potential value in diagnosis and therapy. Our aim was to evaluate miRNA patterns in serum and bile of patients with PSC and/or CC.
methodsSerum and bile from consecutive patients with PSC (n = 40 (serum), n = 52 (bile)), CC (n = 31 (serum), n = 19 (bile)) and patients with CC complicating PSC (PSC/CC) (n = 12 (bile)) were analyzed in a cross-sectional study between 2009 and 2012. As additional control serum samples from healthy individuals were analyzed (n = 12). The miRNA levels in serum and bile were determined with global miRNA profiling and subsequent miRNA-specific polymerase chain reaction-mediated validation.
resultsSerum analysis revealed significant differences for miR-1281 (p = 0.001), miR-126 (p = 0.001), miR-26a (p = 0.001), miR-30b (p = 0.001) and miR-122 (p = 0.034) between patients with PSC and patients with CC. All validated miRNAs were significantly lower in healthy individuals. MiR-412 (p = 0.001), miR-640 (p = 0.001), miR-1537 (p = 0.003) and miR-3189 (p = 0.001) were significantly different between patients with PSC and PSC/CC in bile.
conclusionsPatients with PSC and/or CC have distinct miRNA profiles in serum and bile. Furthermore, miRNA concentrations are different in bile of patients with CC on top of PSC indicating the potential diagnostic value of these miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.